Pfizer will use the company's diagnostic devices for expanded gastroenterology clinical trials.
Exalenz Bioscience Ltd. (TASE:EXEN) will sell more of its diagnostic devices to Pfizer Ltd. (NYSE: PFZ; LSE: PFE) for use in gastroenterology clinical trials that Pfizer is conducting. The company did not disclose the size of the new deal.
Pfizer also plans to expand the use of Exalenz's BID device for use in new clinical trials relating to the liver and digestive system.
Published by Globes [online], Israel business news - www.globes-online.com - on December 24, 2007
© Copyright of Globes Publisher Itonut (1983) Ltd. 2007